paris- Clasoteron is the first real breakthrough in the treatment of acne, after many decades during which anti-therapeutic treatments for this skin disease were not developed. While the promising treatment began use in the United States several months ago, the timing of its availability worldwide is still unknown.
“The most promising treatment for clascutiron is that it counteracts the hormones that cause acne in a new way,” American dermatologist John Barbieri told AFP.
Since the end of 2021, American doctors have been able to prescribe the new ointment that treats acne, which is a skin disease from which people rarely escape during their lives.
Acne, which is the appearance of pimples on the skin and oily skin, affects about three out of four adolescents. A large number of adults are also affected by this skin disease.
The most promising treatment for claskosterone is that it counteracts the hormones that cause acne in a new way.
There is a scarcity of therapeutic developments to confront this very common disease, although research on other details, such as the role of diet in the emergence of acne, has recently developed. Before the discovery of claskosterone, anti-acne treatments saw no progress for nearly 40 years.
The topical treatments are divided into two main categories, the first is the treatment that eliminates the bacteria that causes acne by taking antibiotics, while the second treatment works to reduce the accumulation of dead skin cells that promote inflammation. As for clascosterone, it makes skin cells less responsive to the hormones that produce sebum exudate, an oily substance that acne sufferers produce in excess.
Other oral treatments also work on the hormonal level, but they are usually birth control pills, so they are only prescribed to women. And through its direct effect on the production of hormones, it leads to more serious side effects than acne.
However, any new effect mechanism cannot guarantee the effectiveness of the drug, as it must be proven that the latter has positive results, which happened in the case of clascutorone, which was treated by a study published in the journal in 2020. “Gamma Dermatology” and concluded that this drug is more effective than the alternative treatment given to patients automatically, it also does not lead to serious side effects.
The results of this study were sufficient to allow the US authorities to allow the use of clascuteron. But this new treatment isn’t magic or a revolution against acne.
“The study did not compare clascosterone with existing treatments, so we do not know if the new treatment is better,” French dermatologist Emily Spidian told AFP.
Despite this, she notes, the new drug is “very interesting” because it gives new hope to patients who are reluctant to use other drugs, or it can be added to these drugs to increase their effectiveness.
In Europe, the question of a new treatment is not currently on the table, and there is no indication that clascutorone will be available anytime soon.
◙ Acne, which is the appearance of pimples on the skin and oily skin, affects about three out of four adolescents
This delay is not due to the reluctance of the health authorities to study the subject. The European Medicines Agency tells AFP that it has not yet begun to evaluate the drug. As for the problem at present, it is related to the options of the Swiss company “Cosmo Pharma”, the manufacturer of the drug.
“Because we are a very small group, we initially focused on the issue of licensing the use of the drug in the United States, which is the largest market in the world,” says Diana Harport, the person responsible for the department of dermatology at ” Cosmo, where another company, “Sun Pharma”, distributes the drug. Currently, Harport believes that the market for anti-dermatological drugs does not interest pharmaceutical giants such as the American “Pfizer” and the French “Sanofi”, and then “Cosmo” should find a different partner in each country.
During the publication of its quarterly results at the end of last July, “Cosmo” indicated that it had found a partner to distribute the drug in China. But it has not made similar progress in any European country.
The company attributes the reason it took so long to find a distribution partner to the prolonged market slowdown due to the coronavirus pandemic, but not all observers are happy with this justification.
“The market for pharmaceutical and dermatological products is somewhat booming,” financial analyst Jamila Al-Boughrini told AFP, adding: “I think it is related to mistakes made in the strategy adopted by the group.”
Al-Boukrini, who finds it difficult to understand why the European authorities have not released any evaluation of the drug, indicates that “Cosmo” has resorted to bad options in recent years, one of which is the group’s desire to its only product for the dermatology department, which is clascuterone, but it failed due to the lack of interest from buyers.with this medicine.
“Wasn’t the middle attractive…?” she asks, as it is a difficult step to increase buyers’ interest in a treatment that has not been proven to be more effective than other drugs available in the market.